vTv Therapeutics Inc. (VTVT) Income Statement
VTVT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVTVT revenue and net income
VTVT profit margins
VTVT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −101.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VTVT quarterly EPS vs estimates
vTv Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $-1.07).
VTVT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $9,000 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291,000 | $634,000 |
| Cost of revenue | $16,000 | $89,000 | $90,000 | $92,000 | $89,000 | $11.0M | $15.1M | $23.0M | $39.6M | $45.7M |
| Gross profit | −$16,000 | $1.0M | −$90,000 | $2.0M | $4.0M | −$4.6M | −$12.4M | −$10.6M | −$39.3M | −$45.1M |
| Research & development | $17.9M | $11.5M | $13.6M | $12.4M | $13.3M | $11.0M | $15.1M | $23.0M | $39.6M | $45.7M |
| Sales, general & admin | $14.9M | $13.7M | $11.9M | $12.2M | $12.3M | $7.3M | $8.5M | $9.2M | $11.3M | $9.9M |
| Total operating expenses | $32.8M | $25.2M | $25.5M | $24.6M | $25.7M | $7.3M | $23.7M | $32.3M | $51.0M | $55.7M |
| Operating income | −$32.8M | −$24.2M | −$25.5M | −$22.5M | −$21.7M | −$11.9M | −$20.9M | −$19.8M | −$50.7M | −$55.0M |
| Interest income | $1.9M | $1.6M | $536,000 | $352,000 | $1,000 | $12,000 | $53,000 | $61,000 | $117,000 | $87,000 |
| Interest expense | $6,000 | $0 | $13,000 | $15,000 | $12,000 | $692,000 | $1.8M | $3.3M | $3.1M | $398,000 |
| Income before taxes | −$31.1M | −$22.6M | −$26.0M | −$24.9M | −$17.6M | −$12.8M | −$21.8M | −$23.6M | −$53.8M | −$55.4M |
| Income taxes | — | $100,000 | −$5.7M | $200,000 | $115,000 | −$4.0M | $100,000 | $200,000 | $800,000 | −$39.0M |
| Net income | −$27.0M | −$18.5M | −$20.2M | −$19.2M | −$13.0M | −$8.5M | −$21.9M | −$7.9M | −$16.1M | −$16.4M |
| EBITDA | −$31.1M | −$22.5M | −$25.9M | −$24.8M | −$17.5M | −$12.0M | −$20.0M | −$20.1M | −$50.6M | −$54.7M |
| EPS (diluted) | −$3.35 | −$3.42 | −$5.00 | −$10.00 | −$4.51 | −$8.38 | −$11.24 | −$28.80 | −$66.80 | −$52.42 |
| Gross margin | — | 100.0% | −1,000.0% | 100.0% | 100.0% | −71.7% | −447.0% | −85.3% | −13,522.0% | −7,115.8% |
| Operating margin | — | −2,377.6% | −283,355.6% | −1,116.9% | −540.9% | −184.8% | −755.9% | −159.4% | −17,416.5% | −8,678.2% |
| Net margin | — | −1,815.3% | −225,000.0% | −949.7% | −324.3% | −132.5% | −793.7% | −63.6% | −5,547.8% | −2,579.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $36.8M | $0 | $0 | $0 | $0 | $17,000 | $0 | $0 | $1.0M | $0 | $0 |
| Cost of revenue | — | $1,000 | $2,000 | — | $3,000 | $9,000 | $22,000 | $22,000 | $23,000 | $22,000 | $23,000 | $22,000 |
| Gross profit | — | $36.8M | −$2,000 | — | −$3,000 | −$9,000 | −$5,000 | −$22,000 | −$23,000 | $1.0M | −$23,000 | −$22,000 |
| Research & development | $8.8M | $9.0M | $3.9M | $7.0M | $4.1M | $2.8M | $2.2M | $3.2M | $3.4M | $2.6M | $2.1M | $2.8M |
| Sales, general & admin | $5.2M | $4.6M | $4.0M | $3.7M | $3.6M | $3.7M | $2.7M | $3.3M | $3.7M | $4.0M | $2.6M | $2.5M |
| Total operating expenses | $13.9M | $13.6M | $7.9M | $10.7M | $7.7M | $6.5M | $4.9M | $6.5M | $7.2M | $6.6M | $4.7M | $5.4M |
| Operating income | −$13.9M | $23.3M | −$7.9M | −$10.7M | −$7.7M | −$6.5M | −$4.9M | −$6.5M | −$7.2M | −$5.6M | −$4.7M | −$5.4M |
| Interest income | $812,000 | $838,000 | $865,000 | $399,000 | $275,000 | $331,000 | $429,000 | $504,000 | $553,000 | $79,000 | $88,000 | $131,000 |
| Interest expense | — | — | $1,000 | $5,000 | — | — | $0 | $0 | $0 | — | $7,000 | $4,000 |
| Income before taxes | −$13.1M | $24.1M | −$7.1M | −$10.3M | −$7.4M | −$6.2M | −$4.4M | −$5.8M | −$6.4M | −$5.9M | −$4.4M | −$8.5M |
| Income taxes | — | — | −$2.5M | — | — | — | $2.4M | −$4.8M | −$1.2M | $100,000 | −$963,000 | −$3.3M |
| Net income | −$13.1M | $24.1M | −$7.1M | −$8.7M | −$6.0M | −$5.1M | −$3.6M | −$4.8M | −$5.2M | −$4.9M | −$3.5M | −$6.7M |
| EBITDA | −$13.1M | $24.1M | −$7.1M | −$10.3M | −$7.4M | −$6.2M | −$4.4M | −$5.8M | −$6.4M | −$5.9M | −$4.4M | −$8.5M |
| EPS (diluted) | −$1.05 | $1.65 | −$0.58 | −$1.08 | −$0.92 | −$0.77 | −$0.55 | −$0.88 | −$0.81 | −$1.17 | −$1.67 | −$3.20 |
| Gross margin | — | 100.0% | — | — | — | — | −29.4% | — | — | 100.0% | — | — |
| Operating margin | — | 63.1% | — | — | — | — | −28,776.5% | — | — | −562.7% | — | — |
| Net margin | — | 65.5% | — | — | — | — | −21,376.5% | — | — | −486.5% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VTVT's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VTVT financial results
vTv Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $27.0 million. Diluted earnings per share came to −$3.35.
See the VTVT stock overview for the latest quote and news, or the VTVT chart for price history and technical indicators.
VTVT income statement FAQ
Does vTv Therapeutics have revenue?
vTv Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is vTv Therapeutics profitable?
No. vTv Therapeutics reported a net loss of $27.0 million in fiscal 2025.
How much does vTv Therapeutics spend on research and development?
vTv Therapeutics spent $17.9 million on research and development in fiscal 2025.
What are vTv Therapeutics's earnings per share?
vTv Therapeutics earned $-3.35 per diluted share in fiscal 2025, compared with $-3.42 a year earlier.
When will vTv Therapeutics report its next earnings?
vTv Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does vTv Therapeutics's fiscal year end?
vTv Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.